结核危重症患者的诊断、治疗与结局:一项人群研究(2008-2018)
ICU死亡率24.7%(232/940),住院死亡率41.1%(386/940);校正后延迟抗结核治疗与住院死亡率升高相关,11年间APACHE IV校正SMR无改善。
要点
- ICU及住院死亡率分别为24.7%与41.1%,11年间校正SMR未见改善。
- ICU死亡者中22.8%从未接受抗结核药物,提示治疗延迟问题突出。
- 302例(32.1%)仅靠MTB培养确诊,其中仅31.1%同时行MTB PCR,PCR或可提高诊断率。
核心结论
- 香港ICU结核患者十年间生存未改善,死亡率仍高。
- 校正混杂因素后,延迟抗结核治疗与住院死亡率升高直接相关。
- MTB PCR有望提高诊断率并促进早期治疗。
研究设计与样本
- 基于人群的多中心回顾性队列研究,覆盖香港全部15个公立成人ICU。
- 纳入2008年4月1日至2019年3月31日收治的患者。
- 采用广义线性模型分析治疗延迟对住院死亡率的影响,Mann-Kendall趋势检验分析SMR趋势。
主要发现
- ICU死亡率24.7%(232/940),住院死亡率41.1%(386/940)。
- ICU死亡患者中22.8%(53/232)从未接受抗结核药物。
- 研究期间结核ICU患者SMR无变化(Kendall's τb=0.37,p=0.876)。
- 校正年龄、Charlson合并症指数、APACHE IV、白蛋白、血管活性药、机械通气及肾脏替代治疗后,延迟结核治疗与住院死亡率直接相关。
- 302/940(32.1%)仅通过MTB培养确诊,该组仅31.1%(94/302)同时行MTB PCR。
关键数值与推荐
- ICU死亡率24.7%(232/940),住院死亡率41.1%(386/940)。
- ICU死亡者中22.8%(53/232)未接受抗结核药物。
- SMR趋势检验Kendall's τb=0.37,p=0.876。
- 仅培养确诊者302/940(32.1%),其中行MTB PCR者31.1%(94/302)。
临床怎么用
- 对ICU疑似结核患者应尽早启动抗结核治疗,避免治疗延迟。
- 对培养阳性但涂片或PCR阴性者,应积极加做MTB PCR以提高诊断率。
- 将结核纳入危重症鉴别诊断并关注其较高住院死亡率。
局限性
- 为回顾性队列研究,仅纳入培养阳性患者,可能遗漏培养阴性病例。
- 研究限于香港公立成人ICU,外推需谨慎。
- 原文未报告治疗延迟的具体定义阈值及效应量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) is a preventable and curable disease, but mortality remains high among those who develop sepsis and critical illness from TB. METHODS: This was a population-based, multicentre retrospective cohort study of patients admitted to all 15 publicly funded Hong Kong adult intensive care units (ICUs) between 1 April 2008 and 31 March 2019. 940 adult critically ill patients with at least one positive Mycobacterium tuberculosis (MTB) culture were identified out of 133 858 ICU admissions. Generalised linear modelling was used to determine the impact of delay in TB treatment on hospital mortality. Trend of annual Acute Physiology and Chronic Health Evaluation (APACHE) IV-adjusted standardised mortality ratio (SMR) over the 11-year period was analysed by Mann-Kendall's trend test. RESULTS: ICU and hospital mortality were 24.7% (232/940) and 41.1% (386/940), respectively. Of those who died in the ICU, 22.8% (53/232) never received antituberculosis drugs. SMR for ICU patients with TB remained unchanged over the study period (Kendall's τb=0.37, p=0.876). After adjustment for age, Charlson comorbidity index, APACHE IV, albumin, vasopressors, mechanical ventilation and renal replacement therapy, delayed TB treatment was directly associated with hospital mortality. In 302/940 (32.1%) of patients, TB could only be established from MTB cultures alone as Ziehl-Neelsen staining or PCR was either not performed or negative. Among this group, only 31.1% (94/302) had concurrent MTB PCR performed. CONCLUSIONS: Survival of ICU patients with TB has not improved over the last decade and mortality remains high. Delay in TB treatment was associated with higher hospital mortality. Use of MTB PCR may improve diagnostic yield and facilitate early treatment.
引用
- So C, Ling L, Wong WT, et al. Population study on diagnosis, treatment and outcomes of critically ill patients with tuberculosis (2008-2018). Thorax. 2022. PMID: 35981883. doi:10.1136/thorax-2022-218868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。